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Periodontal disease is a chronic inflammatory disease of the oral cavity affecting the
soft- and hard-supporting structures of the teeth (1, 2). Although bacterial in etiology,
current findings imply that the pathogenesis of periodontitis is mediated by the host’s
response (3). Corticosteroids can act as host’s modulation agents and represent a thera-
peutical approach in periodontal therapy (4–6). One of the mostly used corticosteroids
in clinical practice is betamethasone dipropionate (BDP). Therapeutically, it is used in
the treatment of periodontal disease by local application in the periodontal pocket, after
scaling and root planing. Compared to other corticosteroids intended for local applica-
tion, such as hydrocortisone or triamcinolone acetonide, BDP shows greater anti-inflam-
matory activity probably due to stabilization of lysosomal membranes and blocking the
actions of the invasive mediators of inflammation (6, 7).
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A simple RP HPLC method for quantification of betame-
thasone dipropionate (BDP) in gingival crevicular fluid
(GCF) has been developed and validated. GCF repre-
sents a valuable matrix for therapeutic monitoring of
drugs used in the treatment of periodontal disease. The
proposed method involves single step extraction for
sample preparation. The calibration curve for BDP was
linear over the concentration range of 0.10–2.00 µg mL–1
(R2 = 0.9971). RSD values of intra- and inter-day preci-
sion ranged 2.2–4.5 and 1.6–5.7 %, while accuracy values
were higher than 96.6 and 97.0 %, respectively. The de-
scribed method can be successfully applied for determi-
nation of betamethasone concentrations in GCF obtained
from patients with chronic periodontitis after local treat-
ment with BDP cream 0.5 mg g–1.
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According to our knowledge, no HPLC method for determination of BDP concen-
tration in gingival crevicular fluid (GCF) could be found in literature, while some RP
HPLC and HPLC-MS methods have been developed for determination of BDP in biolo-
gical samples (8, 9).
Thus, the aim of our study was to develop, optimize and validate a new bioana-
lytical HPLC method for determination of BDP in GCF.
EXPERIMENTAL
Chemicals and materials
Betamethasone dipropionate and alclomethasone dipropionate (internal standard,
IS) were provided by Farmabios (Italy) and Crystalpharma (Spain), respectively.
Methanol (HPLC grade) was supplied by Merck, Germany and potassium dihydro-
gen phosphate (analytical grade) was purchased from Fluka, Switzerland. HPLC grade
water was used for chromatographic analysis. Whatman 3MM chromatography paper
strips 2 x 5 mm (Whatman Lab Sales Ltd., UK) were used for GCF collection. Human se-
rum was obtained from healthy volunteers from the Department of Periodontology, Fac-
ulty of Dentistry, University of »Ss. Cyril and Methodius«, Skopje, Macedonia.
Collection of GCF samples
GCF samples were obtained from fifty patients suffering from localized periodon-
titis at the end of the periodontal treatment (one week after the beginning of the scaling
and root planinig procedure). Quadrants consisting of 5 teeth were treated with 0.1 mL
0.5 mg g–1 BDP cream containing 27 µg betamethasone dipropionate (Beloderm® cream
0.5 mg g–1, Belupo, Croatia), using blunt needle. Samples for analysis were taken 15
minutes after treatment. Patients were in good general health and did not take any anti-
biotic or anti-inflammatory drug in the previous three months. The procedure was ap-
proved by the Ethical committee of Faculty of Dentistry, University of »Ss. Cyril and
Methodius«, Skopje, Macedonia. GCF was collected applying the method of Koss et al.
(10) and taken by placing 2 x 5-mm Whatman paper strips into the pocket (depth 4–6
mm) until mild resistance was felt and left there for 30 s. Strips contaminated with blood
were excluded from analysis.
Apparatus and chromatographic conditions
The HPLC analysis was conducted on Agilent 1100 series (USA) equipped with UV
diode array detector. The chromatographic separation was performed on Purospher
STAR RP 18-e 120 Å, 150 x 4.6 mm, 5-µm, using LiChroCART® 4-4 guard column (Merck,
Germany). The HPLC system operated at 25 °C with MeOH/0.04 mol L–1 KH2PO4
(70:30, V/V) as mobile phase. Flow rate was 1.3 mL min–1. The injection volume was
100 µL. UV detection was performed at 245 nm. The total run time for the HPLC analysis
was 14 min.
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Preparation of standard solutions and quality control (QC) samples
Stock standard solutions of betamethasone dipropionate (1.00 mg mL–1) and alclo-
methasone dipropionate (1.00 mg mL–1) were prepared in methanol and refrigerated at 4
°C. Working standard solutions of BDP were made daily by diluting the stock standard
solution of BDP with mobile phase to concentrations of 50.00, 125.00, 250.00, 375.00 and
500.00 mg mL–1, respectively. Working standard solution of IS was made daily by dilut-
ing the stock standard solution of IS with mobile phase to concentrations of 100.00 mg
mL–1. Calculations were performed assuming a volume of one mL GCF. It is based on the
volume that could be collected in the periodontal pocket and which is consistent with
dental practitioner experience. Calibration curve standard solutions were prepared using
working standard solutions of BDP and IS on six paper strips previously spiked with 1
mL of serum, in the following manner: One mL of separate BDP working standard solu-
tion was added to separate paper strip, 10 mL of IS working standard solution was added
to each paper strip. Paper strips were extracted with 500 µL MeOH/H2O mixture (70:30,
V/V). Final concentrations of calibration curve standard solutions were 0.10, 0.25, 0.50,
0.75, 1.00 and 2.00 mg mL–1. The starting calibration curve standard solution containing
2.00 mg mL–1 BDP was prepared from the stock standard solution of BDP in methanol.
QC samples were prepared in the same manner as calibration curve standard solutions
in concentrations of 0.10, 0.25, 1.00 and 1.75 mg mL–1 and stored at –20 °C. GCF exists as
a serum transudate, therefore QC samples and calibration curve standard solutions were
prepared in serum because GCF is not commercially available nor easily collectable in
large volumes (11, 12).
GCF sample preparation
After collection of GCF, paper strips were removed and placed in preweighted
Eppendorf tubes and kept at –20 °C until analysis. Before the HPLC analysis, GCF sam-
ples were thawed at room temperature. 10 mL from 100 mg mL–1 IS solution was added
to the GCF sample. After adding a mixture of methanol/water (70:30, V/V) as an extract-
ing solvent up to volume of 500 mL, the GCF sample solutions were Vortex mixed for 3
minutes. The liquid content of the tubes was transferred to glass autosampler vials. A
100-mL aliquot was injected into chromatographic system. The mass of the fluid was cal-
culated from the differences between masses of the strips with GCF and dry strips. The
obtained value, expressed as mg, was converted to volume in mL assuming the density of
GCF was 1 mg mL–1 (13).
Validation procedure for the bioanalytical HPLC method
The validation of the developed bioanalytical RP HPLC method for determination
of BDP in GCF was performed according to EMEA Guideline for validation of bioana-
lytical methods (14).
The calibration line was constructed with six calibration standards in the range from
0.10 to 2.00 mg mL–1 BDP, including LLOQ and the upper limit of quantification (ULOQ).
The calibration curve was obtained using linear regression analysis of BDP peak area to
internal standard peak area ratio vs. concentration. Limit of detection (LOD) was calcu-
lated as the concentration level resulting in peak area three times the basiline noise
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while lower limit of quantifisation (LLOQ) was calculated as analyte response area at
least five times the blank respose. Analyte calculated concentration sholud be at repro-
ducible with a precision of £ 20 % and accuracy of 80.0–120.0 %.
Selectivity. – Selectivity of the method was investigated by comparing blank GCF
sample solutions and QC sample solutions containing 0.10 mg mL–1 BDP.
Accuracy and precision. – Intra-day accuracy and precision were determined using
five replicates of each of the following QC sample solutions: 0.10, 0.25, 1.00 and 1.75 mg
mL–1 which represent LLOQ, low QC sample (LQC), medium QC sample (MQC) and
high QC sample (HQC), respectively. The QC sample solutions were analyzed on the
same day to establish intra-day accuracy and precision and on three different days to in-
vestigate inter-day accuracy and precision.
Recovery. – The extraction recovery for betamethasone dipropionate and aclometha-
sone dipropionate were calculated by comparing the peak areas measured after extrac-
tion of five replicates of QC sample solutions in the following concentrations: 0.10, 0.25,
1.00 and 1.75 mg mL–1 with peak areas of solutions of the same concentration prepared in
mobile phase.
Stability. – BDP sample solution stability was tested by chromatographic analysis of
QC samples at LQC and HQC levels. The freeze-thaw stability (36 h at –20 °C, three cy-
cles), short-term stability (2 h, room temperature), long-term stability (14 days, –20 °C)




During preliminary investigations, mobile phase composition and flow rate of the
mobile phase were optimized. Several mobile phases containing buffer 0.04 mol L–1
KH2PO4 and methanol were investigated where the composition of the organic phase
varied from 60–80 % (organic phase/buffer, V/V). The best result was obtained using
mobile phase containing 30 % 0.04 mol L–1KH2PO4 and 70 % methanol (V/V). The flow
rate was investigated in the range from 0.8–2.0 mL min–1 and the final flow rate was set
at 1.3 mL min–1.
HPLC method validation
Linearity. – Linearity was observed within the range 0.10–2.00 mg mL–1. Coefficient of
determination R2 was 0.9971, the LOD was 0.05 mg mL–1 and the LLOQ was 0.10 mg mL–1.
Selectivity. – The chromatograms of blank GCF and blank GCF spiked with BDP and
IS are presented in Fig. 1.
As shown in Fig. 1b, BDP and the IS were well separated under the applied HPLC
conditions and resolved with good symmetry. The retention times for BDP and IS were
11.01 min and 6.5 min, respectively. No endogenous interfering peaks at the retention
times of BDP and IS were observed in blank GCF samples, confirming the selectivity of
the method (Fig. 1a).
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Fig. 1. Representative chromatogram of: a) blank GCF sample, b) QC sample containing 0.10 mg
mL–1 BDP (1) and 2.00 mg mL–1 IS (2), c) patient GCF sample containing 2.00 mg mL–1 IS (2) and 0.25
mg mL–1 BDP (1).
Accuracy and precision. – The intra-day and inter-day accuracy and precision are
shown in Table I.
Intra-day precision ranged from 2.2–4.5 % and intra-day accuracy ranged from
98.7–109.6 %. Inter-day precision and accuracy ranged from 1.6–5.7 % and 97.0–106.0 %,
respectively.
Recovery. – The mean extraction recovery of BDP from the matrix at four concentra-
tion levels (0.10, 0.25, 1.00 and 1.75 mg mL–1) were 87.9, 99.6, 101.0 and 99.5 %, respec-
tively. The recovery for the internal standard, alclomethasone dipropionate, was 98.2 %.
The recovery of BDP from the matrix, using the described procedure, was consistent and
efficient.
Stability. – The stability experiments were aimed at testing all possible conditions
that samples may encounter between collection and analysis. Stock solution of BDP and
IS were stable at room temperature for 24 h (recovery: 99.5 and 99.8 %, respectively) and
at 2–8 °C for one month (recovery: 99.1 and 98.5 %, respectively).
The results showed that GCF samples spiked with BDP are stable after three freeze-
-thaw cycles, after 16 hours in the autosampler and at room temperature for 2 hours. The
study also indicated that samples could be kept frozen at –20 °C for two weeks. The re-
sults are presented in Table II.
Analysis of patient GCF samples
The validated HPLC method was applied for determination of BDP concentrations
in GCF samples obtained from patients after the local periodontal treatment with BDP
0.5 mg g–1 cream. A representative chromatogram of a patient GCF sample with BDP is
shown in Fig. 1c.
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Table I. Intra-day and inter-day accuracy and precision









0.100 0.109 ± 0.004 109.6 3.5
0.250 0.246 ± 0.009 99.7 4.0
1.000 0.967 ± 0.025 96.6 2.2
1.750 1.728 ± 0.078 98.7 4.5
Inter-day assay
0.100 0.106 ± 0.152 106.0 4.4
0.250 0.247 ± 4.651 99.1 3.3
1.000 0.969 ± 2.231 97.0 1.6
1.750 1.767 ± 0.101 101.0 5.7
a Each sample solution contains 2.00 mg mL–1 IS.
b Mean ± SD, n = 5.
The concentrations of BDP in analyzed GCF varied in the range 0.10–1.80 mg mL–1
per collected sample. The variability in concentrations of BDP in GCF among patients is
probably a result of different pocket depths, as assumed by Tsai et al. (15), since deeper
periodontal pockets contain larger volumes of excreted GCF.
CONCLUSIONS
An isocratic RP HPLC method with UV detection has been developed and validated
for determination of BDP in GCF. Alclomethasone was used as internal standard. The
simple extraction of BDP with water-methanol mixture without sample concentration,
evaporation or reconstitution yielded high value of recoveries. Further, the validation re-
sults show that the proposed bioanalytical RP HPLC method is suitable for analysis of
BDP in GCF and therefore can be applied for therapeutic drug monitoring in patients
undergoing therapy.
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